Braxia Scientific Corp.
BRAXF · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Revenue | $2 | $1 | $1 | $0 |
| % Growth | 26.7% | 47.5% | 475,547.2% | – |
| Cost of Goods Sold | $2 | $5 | $4 | $0 |
| Gross Profit | $0 | -$3 | -$3 | -$0 |
| % Margin | 9.1% | -220.7% | -286.7% | -4,219.8% |
| R&D Expenses | $0 | $0 | $2 | $0 |
| G&A Expenses | $5 | $6 | $6 | $0 |
| SG&A Expenses | $6 | $7 | $8 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $2 | $0 |
| Other Operating Expenses | $2 | $0 | $1 | $0 |
| Operating Expenses | $8 | $7 | $11 | $0 |
| Operating Income | -$7 | -$7 | -$11 | -$0 |
| % Margin | -397% | -481.4% | -1,045.4% | -81,353.8% |
| Other Income/Exp. Net | -$6 | -$5 | -$78 | -$3 |
| Pre-Tax Income | -$13 | -$12 | -$88 | -$0 |
| Tax Expense | -$0 | -$0 | $0 | $0 |
| Net Income | -$13 | -$12 | -$89 | -$0 |
| % Margin | -697.5% | -815.9% | -8,809.1% | -81,473.1% |
| EPS | -0.058 | -0.069 | -0.56 | -0.004 |
| % Growth | 16.9% | 87.6% | -12,627.3% | – |
| EPS Diluted | -0.058 | -0.069 | -0.56 | -0.004 |
| Weighted Avg Shares Out | 228 | 175 | 158 | 39 |
| Weighted Avg Shares Out Dil | 228 | 175 | 158 | 39 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $0 | $0 |
| EBITDA | -$13 | -$7 | -$89 | -$3 |
| % Margin | -674.2% | -479.9% | -8,806.8% | -1,555,754.2% |